Zobrazeno 1 - 10
of 85
pro vyhledávání: '"E. Kuligowski"'
Autor:
E. Ronchi, J. Wahlqvist, A. Ardinge, A. Rohaert, S. M. V. Gwynne, G. Rein, H. Mitchell, N. Kalogeropoulos, M. Kinateder, N. Bénichou, E. Kuligowski, A. Kimball
Publikováno v:
Natural Hazards. 117:1493-1519
This paper introduces a protocol for the verification of multi-physics wildfire evacuation models, including a set of tests used to ensure that the conceptual modelling representation of each modelling layer is accurately implemented, as well as the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::024e186bb46a63bcfec7222b105e33c7
https://doi.org/10.1007/s11069-023-05913-2
https://doi.org/10.1007/s11069-023-05913-2
Autor:
Andrew Blauvelt, Jacek C. Szepietowski, Kim Papp, Eric L. Simpson, Jonathan I. Silverberg, Brian S. Kim, Shawn G. Kwatra, Michael E. Kuligowski, May E. Venturanza, Shaoceng Wei, Leon Kircik
Publikováno v:
Journal of the American Academy of Dermatology. 88:651-653
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::741063c655e9834bd7c7449f9cd390cc
https://doi.org/10.1016/j.jaad.2022.09.010
https://doi.org/10.1016/j.jaad.2022.09.010
Autor:
Andrew Blauvelt, Leon Kircik, Kim A. Papp, Eric L. Simpson, Jonathan I. Silverberg, Brian S. Kim, Shawn G. Kwatra, Michael E. Kuligowski, May E. Venturanza, Shaoceng Wei, Jacek C. Szepietowski
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 37:137-146
Ruxolitinib cream is a topical formulation of ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor.To report timing and magnitude of effect of ruxolitinib cream on itch in patients with atopic dermatitis (AD), a highly pruritic inflammatory skin diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd79211ea0eb8edec513e393a2f2fdf8
https://doi.org/10.1111/jdv.18571
https://doi.org/10.1111/jdv.18571
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xuejun Chen, Xiang Liu, Xiaohua Gong, Xing Liu, Swamy Yeleswaram, Evan Cimino, Ryan F. McGee, Michael E. Kuligowski
Publikováno v:
American Journal of Clinical Dermatology
Background Pathogenesis of atopic dermatitis (AD) involves the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. A cream formulation of ruxolitinib, a potent selective JAK1/JAK2 inhibitor, was developed for topical d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c6efe61d4a982622ed87f102c2a8395
https://doi.org/10.1007/s40257-021-00610-x
https://doi.org/10.1007/s40257-021-00610-x
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Donald Y.M. Leung, Amy S. Paller, Andrea L. Zaenglein, Wynnis L. Tom, Peck Y. Ong, May E. Venturanza, Michael E. Kuligowski, Qian Li, Xiaohua Gong, Mark S. Lee
Publikováno v:
Annals of Allergy, Asthma & Immunology. 130:500-507.e3
Therapies for children with atopic dermatitis (AD) have safety and tolerability concerns that may limit long-term use. Ruxolitinib cream, a Janus kinase (JAK) inhibitor, is effective and well tolerated in adolescents and adults with AD.The primary ob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46fd47ccf03413ea01566fbf5341396e
https://doi.org/10.1016/j.anai.2022.12.033
https://doi.org/10.1016/j.anai.2022.12.033
Publikováno v:
Journal of the American Academy of Dermatology. 82:1305-1313
Atopic dermatitis (AD), a chronic, highly pruritic skin disorder, impairs quality of life (QoL). Janus kinase inhibitors suppress inflammatory and pruritus-associated cytokine signaling in AD.To report the effects of ruxolitinib (RUX) cream on itch a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::249329239ee536c97c1e12fefb142011
https://doi.org/10.1016/j.jaad.2020.02.009
https://doi.org/10.1016/j.jaad.2020.02.009
Autor:
Kim Papp, Jacek C. Szepietowski, Leon Kircik, Darryl Toth, Lawrence F. Eichenfield, Seth B. Forman, Michael E. Kuligowski, Howard Kallender, Kang Sun, Haobo Ren, Eric L. Simpson
Publikováno v:
Journal of the American Academy of Dermatology.
Ruxolitinib cream demonstrated safety and efficacy over 8 weeks in two double-blind phase 3 atopic dermatitis studies (NCT03745638/NCT03745651).Evaluate long-term safety (LTS) and disease control with ruxolitinib cream.Patients initially randomized t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff69cb1367d0a0c21105774127edbf4
https://pubmed.ncbi.nlm.nih.gov/36574595
https://pubmed.ncbi.nlm.nih.gov/36574595